Trials / Completed
CompletedNCT06018948
Effect of Two Different Doses of Dexmedetomidine Infusion in Morbidly Obese Patients
The Effect of Two Different Doses of Dexmedetomidine Infusion on Oxygenation, Lung Mechanics, and Quality of Recovery in Morbidly Obese Patients: A Prospective Randomized Controlled Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Tanta University · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Compare the effects of two different doses of dexmedetomidine infusion on oxygenation as a primary outcome and on lung mechanics, quality of recovery and perioperative analgesia as secondary outcomes in morbidly obese patients with restrictive lung disease undergoing abdominal surgery.
Detailed description
Dexmedetomidine is a selective α2 receptor agonist and has sympatholytic, analgesic, anti-inflammatory and sedative properties. Dexmedetomidine decreased dead space and improved both lung compliance and oxygenation in chronic obstructive pulmonary disease (COPD) patients undergoing lung cancer surgery. The effects of dexmedetomidine on oxygenation and lung mechanics had been investigated in obstructive lung disease, but there are little information about its effect in morbidly obese patients with restrictive lung disease .
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexmedetomidine 0.6 | Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.6 μg/kg/hr for one hour. |
| DRUG | Dexmedetomidine 0.3 | Patients received a bolus dose of 1μg/kg Dexmedetomidine, 15 minutes after endotracheal intubation over 10 minutes followed by infusion of 0.3 μg/kg/hr for one hour. |
| DRUG | Saline | Patients received over 10 minutes comparable volume of normal saline (0.9%) 15 min after endotracheal intubation followed by infusion. |
Timeline
- Start date
- 2019-09-01
- Primary completion
- 2021-09-30
- Completion
- 2021-09-30
- First posted
- 2023-08-31
- Last updated
- 2023-08-31
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT06018948. Inclusion in this directory is not an endorsement.